Finanzas de Zura Bio Ltd (ZURA)ZURAZura Bio Ltd

Evaluating the bottom line, Zura Bio Ltd maintains a gross margin of N/A. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at N/A, while the net margin is N/A. These profitability ratios, combined with a Return on Equity (ROE) of -72.10%, provide a clear picture of how effectively ZURA converts its operational activities into shareholder value.

In the context of the broader market, ZURA competes directly with industry leaders such as FENC and KYTX. With a market capitalization of $422.61M, it holds a leading position in the sector. When comparing efficiency, ZURA's gross margin of N/A stands against FENC's 95.97% and KYTX's N/A. Such benchmarking helps identify whether Zura Bio Ltd is trading at a premium or discount relative to its financial performance.

Zura Bio has reported consistent net losses, with Q2 2026 showing a net loss of $26.3 million and a GAAP EPS of -0.21, indicating ongoing financial challenges. The current ratio is strong at 12.90, suggesting good liquidity, but the overall financial health is concerning due to widening losses.